<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02596243</url>
  </required_header>
  <id_info>
    <org_study_id>HPV-EU-001</org_study_id>
    <nct_id>NCT02596243</nct_id>
  </id_info>
  <brief_title>Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 2 Clinical Trial to Evaluate the Efficacy and the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation(EP) in HPV Type 16 and/or 18 Positive Patients With Biopsy-proven Cervical Intraepithelial Neoplasia Grade 2(CIN2), Grade 2/3 (CIN2/3), Grade 3(CIN3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genexine, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to access the efficacy and safety of GX-188E according the
      protocol in patients with Cervical Intraepithelial Neoplasia 2, 2/3 or 3 (CIN3)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not provided
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with histopathological regression of cervical lesions to CIN1 or less</measure>
    <time_frame>36 weeks</time_frame>
    <description>The number of participants with cervical lesions regress to CIN1 or less at the 36 week visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Clearance of HPV 16 or 18 in combination with histopathological regression of cervical lesions to CIN1 or less</measure>
    <time_frame>36 weeks</time_frame>
    <description>The number of participants with clearance of HPV 16 or 18 in combination with histopathological regression of cervical lesions to CIN1 or less at the 36 week visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <arm_group>
    <arm_group_label>GX-188E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-188E + EP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + EP</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GX-188E</intervention_name>
    <description>1mg of GX-188E administered IM using EP device at day 0, week 4 and week 12.</description>
    <arm_group_label>GX-188E</arm_group_label>
    <other_name>DNA therapeutic vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.5mL of Placebo administered IM using EP device at day 0, week 4 and week 12.</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Placebo-control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female subjects age 18-60 years

          2. Histologically confirmed HPV-16 or HPV-18 asspcoated CIN2, CIN 2/3 or CIN3 from tissue
             collected less than 10 weeks prior to Vaccination/EP #1 with overall lesion sizes less
             than 50% of the cervix area and no evidence of invasive cancer in any specimen;

          3. Colposcopy is satisfactory based on visualization of the entire squamocolumnar
             junction and the upper limit of the entire aceto-white or suspected CIN disease area;

          4. Healthy subjects as judged by the Investigator based on medical history, PE, and
             normal results for an ECG, CBC, Serum Chemistries, CPK and urinalysis done up to 4
             weeks prior to enrolment;

          5. For women who are not postmenopausal (at least 12 months of nontherapy- induced
             amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to
             remain abstinent or use a highly effective method of contraception during the
             treatment period and throughout Week 36 response evaluation visit.

          6. Able and willing to comply with all study procedures and voluntarily signs informed
             consent form.

        Exclusion Criteria:

          1. Unsatisfactory colposcopy defined as incomplete visualization of the entire
             squamocolumnar junction and the upper limit of the entire aceto-white or suspected CIN
             disease area;

          2. Pregnancy or breastfeeding;

          3. Immunosuppression including any concurrent condition requiring the continued use of
             systemic or topical steroids at or near the injection site [deltoid, upper arm]
             (excluding inhaled and eye drop-containing corticosteroids) or the use of
             immunosuppressive agents. All other corticosteroids must be discontinued &gt; 4 weeks
             prior to Day 0 of study vaccine administration; autoimmune disorders, transplant
             recipients;

          4. History of previous therapeutic HPV vaccination (individuals who have been immunized
             with licensed prophylactic HPV vaccines (e.g. Gardasil®, Cervarix®) are not excluded);

          5. Positive serological test for hepatitis C virus or hepatitis B virus surface antigen
             (HBsAg) or human immunodeficiency virus (HIV);

          6. Administration of any blood product within 3 months of enrollment;

          7. Administration of any licensed vaccine within 2 weeks of enrollment (4 weeks for
             measles vaccine);

          8. Participation in a study with an investigational compound or device within 30 days
             prior to signing informed consent;

          9. Cardiac pre-excitation syndromes (such as Wolff-Parkinson-White);

         10. History of seizures (unless seizure free for 5 years);

         11. Tattoos, scars, active lesions/rashes or any implantable leads within 3 cm of the
             intended site of vaccination/EP;

         12. Any electronic medical implants (such as cardiac pacemaker);

         13. Active drug or alcohol use or dependence that, in the opinion of the investigator,
             would interfere with adherence to study requirements;

         14. A tendency for severe haemorrhage following acute trauma;

         15. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
             treatment of either a psychiatric or physical (i.e. infections disease) illness must
             not be enrolled into this study;

         16. Any other conditions judged by the investigator that would limit the evaluation of a
             subject.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terje Raud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tartu University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kersti Kukk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Estonia Medical Centre Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aira Peri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>East Tallinn Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tetiana Tatarchuk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Academy of Medical Sciences of Ukraine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nataliya Lutsenko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Institution, Zaporizhzhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergiy Kartashov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kharkiv medical academy of postgraduate education</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Natalia Rozhkovska, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Multi-profile Medical Center (University Clinic No. 1) of Odesa National Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>East Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10119</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Estonia Medical Centre Foundation</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheil General Hospital &amp; Women's Healthcare Center</name>
      <address>
        <city>Seoul</city>
        <zip>04619</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA Gangnam Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06135</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangnam Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07441</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ehwa Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07985</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>080308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kharkiv medical academy of postgraduate education</name>
      <address>
        <city>Kharkiv</city>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Academy of Medical Sciences of Ukraine</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multi-profile Medical Center (University Clinic No. 1) of Odesa National</name>
      <address>
        <city>Odessa</city>
        <zip>65026</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution Zaporizhzhia Medical Academy of Post-Graduate Education</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69071</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Korea, Republic of</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2015</study_first_posted>
  <last_update_submitted>July 11, 2017</last_update_submitted>
  <last_update_submitted_qc>July 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CIN2, CIN2/3, CIN3</keyword>
  <keyword>Cervical Intraepithelial Neoplasia</keyword>
  <keyword>High-Risk HPV</keyword>
  <keyword>HPV infection</keyword>
  <keyword>precancer Diseases</keyword>
  <keyword>Double Blind</keyword>
  <keyword>Safety/Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

